The anti-neoplastic effect of doxycycline in osteosarcoma as a metalloproteinase (MMP) inhibitor: a systematic review
ConclusionDoxycycline remains a promising chemotherapeutic agent against osteosarcoma via MMP inhibition, showing the need for further in vivo and clinical trials to be carried out in the future.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Clinical Trials | Doxycycline | Laboratory Medicine | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Nutrition | Osteosarcoma | Sarcomas | Tetracycline